Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
Susan E. Dorman(Medical University of South Carolina), Neil W. Schluger(Columbia University), Marc Weiner(The University of Texas at San Antonio Health Science Center), Stefan Goldberg, Masahiro Narita(Public Health – Seattle & King County), Jason E. Stout(Duke University), Beliyou Haile(International Finance Corporation), John L. Johnson(University School), Payam Nahid(University of California, San Francisco), Andrew Vernon(The University of Texas at El Paso), Susan M. Ray(Emory University), Lorna Bozeman(Centers for Disease Control and Prevention), Charles M. Heilig(Centers for Disease Control and Prevention), Eric Bates(University of North Texas), Eric Nuermberger(Johns Hopkins University), P.-J. Feng(Centers for Disease Control and Prevention), Ruth N. Moro(Centers for Disease Control and Prevention), Grace Muzanyi(The University of Texas at San Antonio Health Science Center)
Cited by 110
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
|PubMed|2010|1.1k